Cargando…
Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine
With the National Centralized Drug Procurement policy gradually applied nationally in China, concerns about the effectiveness and safety of bid-winning generic drugs are growing again, but relevant studies are lacking. This real-world, before-and-after study was conducted to explore the clinical eff...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999380/ https://www.ncbi.nlm.nih.gov/pubmed/36909190 http://dx.doi.org/10.3389/fphar.2023.1097600 |
_version_ | 1784903652233707520 |
---|---|
author | Zhang, Chao Ding, Yudan Wu, Zhenzhen Wang, Juan Wu, Xiangping Xie, Weiwei |
author_facet | Zhang, Chao Ding, Yudan Wu, Zhenzhen Wang, Juan Wu, Xiangping Xie, Weiwei |
author_sort | Zhang, Chao |
collection | PubMed |
description | With the National Centralized Drug Procurement policy gradually applied nationally in China, concerns about the effectiveness and safety of bid-winning generic drugs are growing again, but relevant studies are lacking. This real-world, before-and-after study was conducted to explore the clinical effects of switching between two versions of generic olanzapine (one of them was bid-winning product). Pre-and post-switching serum olanzapine concentrations were compared. A total of 30 patients were included and results showed the log-transformed, dose-adjusted concentration of bid-winning generic olanzapine was significantly lower than that of another generic olanzapine, while no significant differences were shown on Clinical Global Impressions Severity of Illness or Improvement ratings before and after switching. This study suggest that a generic version of a psychotropic medication may not be of therapeutic equivalence or bioequivalence with another generic one. Changes in efficacy or tolerability are possible in every switch. Therapeutic drug monitoring could be a valuable tool during switches between generic drugs. Larger prospective clinical studies for other generic psychotropic medications in target populations are warranted. |
format | Online Article Text |
id | pubmed-9999380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99993802023-03-11 Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine Zhang, Chao Ding, Yudan Wu, Zhenzhen Wang, Juan Wu, Xiangping Xie, Weiwei Front Pharmacol Pharmacology With the National Centralized Drug Procurement policy gradually applied nationally in China, concerns about the effectiveness and safety of bid-winning generic drugs are growing again, but relevant studies are lacking. This real-world, before-and-after study was conducted to explore the clinical effects of switching between two versions of generic olanzapine (one of them was bid-winning product). Pre-and post-switching serum olanzapine concentrations were compared. A total of 30 patients were included and results showed the log-transformed, dose-adjusted concentration of bid-winning generic olanzapine was significantly lower than that of another generic olanzapine, while no significant differences were shown on Clinical Global Impressions Severity of Illness or Improvement ratings before and after switching. This study suggest that a generic version of a psychotropic medication may not be of therapeutic equivalence or bioequivalence with another generic one. Changes in efficacy or tolerability are possible in every switch. Therapeutic drug monitoring could be a valuable tool during switches between generic drugs. Larger prospective clinical studies for other generic psychotropic medications in target populations are warranted. Frontiers Media S.A. 2023-02-22 /pmc/articles/PMC9999380/ /pubmed/36909190 http://dx.doi.org/10.3389/fphar.2023.1097600 Text en Copyright © 2023 Zhang, Ding, Wu, Wang, Wu and Xie. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Chao Ding, Yudan Wu, Zhenzhen Wang, Juan Wu, Xiangping Xie, Weiwei Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine |
title | Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine |
title_full | Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine |
title_fullStr | Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine |
title_full_unstemmed | Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine |
title_short | Does China’s competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine |
title_sort | does china’s competitive generic substitution policy deliver equivalent clinical outcomes? a pilot study with two generic formulations of olanzepine |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999380/ https://www.ncbi.nlm.nih.gov/pubmed/36909190 http://dx.doi.org/10.3389/fphar.2023.1097600 |
work_keys_str_mv | AT zhangchao doeschinascompetitivegenericsubstitutionpolicydeliverequivalentclinicaloutcomesapilotstudywithtwogenericformulationsofolanzepine AT dingyudan doeschinascompetitivegenericsubstitutionpolicydeliverequivalentclinicaloutcomesapilotstudywithtwogenericformulationsofolanzepine AT wuzhenzhen doeschinascompetitivegenericsubstitutionpolicydeliverequivalentclinicaloutcomesapilotstudywithtwogenericformulationsofolanzepine AT wangjuan doeschinascompetitivegenericsubstitutionpolicydeliverequivalentclinicaloutcomesapilotstudywithtwogenericformulationsofolanzepine AT wuxiangping doeschinascompetitivegenericsubstitutionpolicydeliverequivalentclinicaloutcomesapilotstudywithtwogenericformulationsofolanzepine AT xieweiwei doeschinascompetitivegenericsubstitutionpolicydeliverequivalentclinicaloutcomesapilotstudywithtwogenericformulationsofolanzepine |